ArticleMaterials (Basel, Switzerland)2026
Multifunctional Xanthan Gum-Hydroxyapatite Composite with Enhanced Dye Adsorption, Antibacterial Activity, and Cytocompatibility.
Article in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hydroxyapatite (HAp) is a promising biomaterial with potential environmental and biomedical applications; however, its surface properties and functional performance can be improved through polymer modification. In this study, a novel hydroxyapatite xanthan (HAp-XAn) composite was developed and investigated for both environmental and biomedical applications. Comprehensive structural and surface analyses were carried out using X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS), scanning electron microscopy (SEM), and atomic force microscopy (AFM) measurements. The biocompatibility of HAp and the HAp-XAn composite was assessed with the aid of the MG63 cell line using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. The findings indicate that both HAp and HAp-XAn exhibit good in vitro cytocompatibility and favorable interactions with osteoblast-like cells, supporting their potential for use in bone-related biomedical applications. The antibacterial properties of HAp and HAp-XAn composites were studied in vitro against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.